GL1X · GenesisL1 explorer

Research workbench

Human SIRT2 in complex with myristoyl thiourea inhibitor, NO.13

Analyse Human SIRT2 in complex with myristoyl thiourea inhibitor, NO.13 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7BOS
Type
protein
Length
284 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
NAD-dependent protein deacetylase sirtuin-2; Myristoyl thiourea inhibitor, NO.13
EC
2.3.1.286
UniProt
Q8IXJ6
Ligands
P6S, F4R, ZN, NH2
Pockets
2 · best druggability 0.82

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANAD-dependent protein deacetylase sirtuin-2 (EC 2.3.1.286)protein28141% helix, 18% strandQ8IXJ6
BMyristoyl thiourea inhibitor, NO.13protein30% helix, 33% strand—

Ligands and binding sites

  • P6S · benzyl hydrogen carbonate · ligand · chains A, B
  • F4R · N-dodecylmethanethioamide · ligand · chains A, B
  • ZN · Zinc ion · metal · chains A
  • NH2 · Amino group · ion · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15680.820.8747F4R
21200.390.7425empty

Interfaces

1 interface between chains.

  • A–B · 396 Ų buried · 8 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 7BOS · Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.